Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
CVS Health (CVS)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-11-04
$81.33+1.71%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
8.52 → 8.53 EPS · FY ending Dec 31, 2027 · 18 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 18 to 18; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CVS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
5 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EPS guidance raised to $7.30 per share in 2026 | EPS guidance is raised to $7.30 per share. | Broken | Adjusted EPS guidance falls below $7.00 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 8 supplied quarters. Management reported: “The Company is increasing its full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.” “The Company is increasing its full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CVS is a large healthcare business with a currently improving earnings and cash flow story, rather than a turnaround based only on future hopes. Its long-term thesis is intact, with recent financial performance in the top half of its industry and management delivering on key priorities, though confidence in the evidence is medium.
The valuation evidence describes CVS as cheap versus peers, with expectations below the model’s view, while also showing a 0.52 peer premium measure. The overall priced-in tag is justified and no fragility gates fired, so the evidence does not point to especially fragile expectations.
Near term, recent results are strong: second-quarter revenue grew 7.3% year over year, and management raised 2026 guidance for both GAAP and adjusted EPS as well as operating cash flow. Revenue and EPS priorities are on track, while cash flow progress is mixed; a recent deep miss and a downward trend in earnings surprises remain risks despite a low stated miss probability.
The multi-year thesis depends on management sustaining the recent improvement and avoiding a guidance reversal, which could damage credibility. Near-term sector support may continue if healthcare bellwethers keep reporting strong results, while weaker job growth could raise recession concerns for healthcare names, including CVS.
Over the next 1 to 3 years, the business setup is supported by better results, raised guidance, and a favorable sector backdrop, but execution and guidance credibility remain central. The long-term thesis is intact, with medium confidence and meaningful risks to monitor. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Free cash flow at least $9.5 billion in fiscal 2026 | Free cash flow rises to at least $9.5 billion. | Under Pressure | Free cash flow falls below $9 billion in FY26 | Free cash flow: $5.654B FY2026-Q2; GAAP. Published target: >= $9.5 billion. Annual target cannot be compared with a quarterly or TTM observation. Aug 5, 20265,654,000,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 4 of 8 supplied quarters. Management reported: “The Company is increasing its full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.” Delivery assessment Nov 4, 2026 |
Operating margin near 13.4% in fiscal 2026 | Profit margin stays near 13.4%. | Under Pressure | Operating margin falls below 12% in FY26 | Operating margin: 3.29% FY2026-Q3; GAAP. Published target: ~13.4%. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 20263.289698 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 8 supplied quarters. Management reported: “The Company is increasing its full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.” “The Company is increasing its full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.” Delivery assessment Nov 4, 2026 |
No major drug price controls limiting revenue | A supporting condition in CVS Health's published investment case. The stated target is No new restrictive drug price regulations. | Intact | New drug price controls are enacted that limit revenue | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue at least $405 billion in fiscal 2026 | Free cash flow rises to at least $9.5 billion. | Under Pressure | Revenue falls below $400 billion in FY26 | Revenue: $108.399B FY2026-Q3; GAAP. Published target: >= $405 billion. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 2026108,399,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$8.41 → $8.53 · observed estimates
$426.70B → $429.85B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $8.41 | $426,700,144,360 | 27 / 23 |
| 2026-07-25 | $8.42 | $426,716,835,060 | 27 / 23 |
| 2026-07-26 | $8.42 | $426,716,835,060 | 27 / 23 |
| 2026-07-27 | $8.43 | $426,275,873,218 | 17 / 18 |
| 2026-07-28 | $8.42 | $426,716,835,060 | 27 / 23 |
| 2026-07-29 | $8.43 | $426,275,873,218 | 17 / 18 |
| 2026-07-30 | $8.42 | $426,716,835,060 | 27 / 23 |
| 2026-07-31 | $8.42 | $426,716,835,060 | 27 / 23 |
| 2026-08-01 | $8.44 | $426,275,873,218 | 17 / 18 |
| 2026-08-02 | $8.44 | $426,275,873,218 | 18 / 18 |
| 2026-08-03 | $8.44 | $426,275,873,218 | 18 / 18 |
| 2026-08-04 | $8.44 | $426,275,873,218 | 18 / 18 |
| 2026-08-05 | $8.44 | $426,275,873,218 | 18 / 18 |
| 2026-08-06 | $8.43 | $426,523,582,110 | 26 / 22 |
| 2026-08-07 | $8.46 | $427,300,270,531 | 17 / 17 |
| 2026-08-08 | $8.47 | $428,421,098,030 | 26 / 22 |
| 2026-08-09 | $8.47 | $428,421,098,030 | 26 / 22 |
| 2026-08-10 | $8.46 | $427,300,270,531 | 17 / 17 |
| 2026-08-11 | $8.48 | $429,198,416,220 | 26 / 22 |
| 2026-08-12 | $8.46 | $427,300,270,531 | 17 / 17 |
| 2026-08-13 | $8.46 | $427,300,270,531 | 17 / 17 |
| 2026-08-14 | $8.46 | $427,300,270,531 | 17 / 17 |
| 2026-08-15 | $8.46 | $427,300,270,531 | 17 / 17 |
| 2026-08-16 | $8.46 | $427,300,270,531 | 17 / 17 |
| 2026-08-17 | $8.46 | $427,300,270,531 | 17 / 17 |
| 2026-08-18 | $8.46 | $427,300,270,531 | 17 / 17 |
| 2026-08-19 | $8.46 | $427,300,270,531 | 17 / 17 |
| 2026-08-20 | $8.49 | $429,211,239,992 | 17 / 17 |
| 2026-08-21 | $8.49 | $429,211,239,992 | 17 / 17 |
| 2026-08-22 | $8.49 | $429,211,239,992 | 17 / 17 |
| 2026-08-23 | $8.49 | $429,211,239,992 | 17 / 17 |
| 2026-08-24 | $8.49 | $429,211,239,992 | 17 / 17 |
| 2026-08-25 | $8.49 | $429,211,239,992 | 17 / 17 |
| 2026-08-26 | $8.49 | $429,108,718,253 | 17 / 17 |
| 2026-08-27 | $8.49 | $429,108,718,253 | 17 / 17 |
| 2026-08-28 | $8.49 | $429,108,718,253 | 17 / 17 |
| 2026-08-29 | $8.49 | $429,195,655,631 | 17 / 17 |
| 2026-08-30 | $8.49 | $429,195,655,631 | 17 / 17 |
| 2026-08-31 | $8.49 | $429,195,655,631 | 17 / 17 |
| 2026-09-01 | $8.49 | $429,195,655,631 | 17 / 17 |
| 2026-09-02 | $8.49 | $429,195,655,631 | 17 / 17 |
| 2026-09-03 | $8.49 | $428,471,900,364 | 17 / 17 |
| 2026-09-04 | $8.49 | $428,471,900,364 | 18 / 17 |
| 2026-09-05 | $8.50 | $428,993,639,494 | 18 / 17 |
| 2026-09-06 | $8.50 | $428,993,639,494 | 18 / 17 |
| 2026-09-07 | $8.50 | $428,993,639,494 | 18 / 17 |
| 2026-09-08 | $8.50 | $428,993,639,494 | 18 / 17 |
| 2026-09-09 | $8.50 | $428,993,639,494 | 18 / 17 |
| 2026-09-10 | $8.51 | $429,224,847,459 | 17 / 17 |
| 2026-09-11 | $8.51 | $429,224,847,459 | 17 / 17 |
| 2026-09-12 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-13 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-14 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-15 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-16 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-17 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-18 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-19 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-20 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-21 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-22 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-23 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-24 | $8.51 | $429,224,847,459 | 18 / 17 |
| 2026-09-25 | $8.51 | $429,585,151,807 | 18 / 17 |
| 2026-09-26 | $8.51 | $429,585,130,155 | 18 / 17 |
| 2026-09-27 | $8.51 | $429,585,130,155 | 18 / 17 |
| 2026-09-28 | $8.51 | $429,585,130,155 | 18 / 17 |
| 2026-09-29 | $8.51 | $429,585,130,155 | 18 / 17 |
| 2026-09-30 | $8.51 | $429,585,130,155 | 18 / 17 |
| 2026-10-01 | $8.51 | $429,585,130,155 | 18 / 17 |
| 2026-10-02 | $8.51 | $429,585,130,155 | 18 / 17 |
| 2026-10-03 | $8.52 | $429,651,912,764 | 18 / 17 |
| 2026-10-04 | $8.52 | $429,651,912,764 | 18 / 17 |
| 2026-10-05 | $8.52 | $429,651,912,764 | 18 / 17 |
| 2026-10-06 | $8.52 | $429,651,912,764 | 18 / 17 |
| 2026-10-07 | $8.52 | $429,740,685,500 | 18 / 17 |
| 2026-10-08 | $8.52 | $429,732,598,544 | 18 / 17 |
| 2026-10-09 | $8.52 | $429,732,598,544 | 18 / 17 |
| 2026-10-10 | $8.52 | $429,732,598,544 | 18 / 17 |
| 2026-10-11 | $8.52 | $429,732,598,544 | 18 / 17 |
| 2026-10-12 | $8.52 | $429,732,598,544 | 18 / 17 |
| 2026-10-13 | $8.52 | $429,732,598,544 | 18 / 17 |
| 2026-10-14 | $8.52 | $429,645,661,166 | 18 / 17 |
| 2026-10-15 | $8.52 | $429,645,661,166 | 18 / 17 |
| 2026-10-16 | $8.52 | $429,645,661,166 | 18 / 17 |
| 2026-10-17 | $8.52 | $429,645,661,166 | 18 / 17 |
| 2026-10-18 | $8.52 | $429,645,661,166 | 18 / 17 |
| 2026-10-19 | $8.52 | $429,645,661,166 | 18 / 17 |
| 2026-10-20 | $8.52 | $429,645,661,166 | 18 / 17 |
| 2026-10-21 | $8.52 | $429,645,661,166 | 18 / 17 |
| 2026-10-22 | $8.52 | $429,848,782,128 | 18 / 17 |
| 2026-10-23 | $8.52 | $429,848,782,128 | 18 / 17 |
| 2026-10-24 | $8.52 | $429,848,782,128 | 18 / 17 |
| 2026-10-25 | $8.52 | $429,848,782,128 | 18 / 17 |
| 2026-10-26 | $8.52 | $429,848,782,128 | 18 / 17 |
| 2026-10-27 | $8.52 | $429,848,782,128 | 18 / 17 |
| 2026-10-28 | $8.52 | $429,848,782,128 | 18 / 17 |
| 2026-10-29 | $8.52 | $429,848,782,128 | 18 / 17 |
| 2026-10-30 | $8.53 | $429,848,782,128 | 18 / 17 |
| 2026-10-31 | $8.53 | $429,848,782,128 | 18 / 17 |
| 2026-11-01 | $8.53 | $429,848,782,128 | 18 / 18 |
| 2026-11-02 | $8.53 | $429,848,782,128 | 18 / 18 |
| 2026-11-03 | $8.53 | $429,848,782,128 | 18 / 18 |
| 2026-11-04 | $8.53 | $429,848,804,764 | 18 / 18 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 25 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 1 cuts · 0 unchanged · 3 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings5 of 5 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.